Triple negative breast cancer (TNBC) is a heterogeneous disease, not only on the molecular level, but also on the pathologic and clinical levels. It also has a distinct epidemiology. TNBCs are frequently of high histologic grade, typically more aggressive and difficult to treat than hormone receptor-positive tumors, and they are associated with a higher risk of early relapse with visceral metastasis after surgery, chemotherapy and/or radiotherapy. The lack of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression precludes the use of targeted therapies in advanced stages, and the only approved systemic treatment option is chemotherapy with or without bevacizumab. In patients with advanced TNBC, responses to chemotherapy occur, but are often of short duration and it is associated with poor prognosis. The median overall survival for patients with metastatic TNBC is about 9-12 months with conventional cytotoxic agents. Given the suboptimal outcomes with chemotherapy, new targeted therapies for TNBC are urgently needed. This review summarizes the clinical efficacy, perspectives and future challenges of using new treatment options for metastatic TNBC, such as poly-ADPribose-polymerase inhibitors, antiandrogen therapies and immune checkpoint inhibitors (antiprogrammed death receptor-1/PD-L1 monoclonal antibodies).
INTRODUCTION
Triple negative breast cancer (TNBC) is defined by the lack of estrogen receptors (ERs) and progesterone receptors (PRs) and by human epidermal growth factor receptor 2 (HER2)-negative status. TNBC accounts for 15-20% of newly diagnosed breast cancer (BC) cases. 1 TNBC is a heterogeneous disease, not only on the molecular level, but also on the pathologic and clinical levels. It also has a distinct epidemiology.
On the pathologic level, high-grade infiltrating ductal carcinoma (not otherwise specified) is the most common histological subtype in TNBC, and this histologic subtype accounts for 90% of all TNBCs. 2 The heterogeneity of TNBC, on the pathologic level, is further highlighted by the high prevalence of rare histopathological subtypes, such as metaplastic (90%), medullary (95%), adenoid cystic (90-100%) and apocrine (40-60%) carcinomas. 3 Early-stage TNBC is associated with a significantly higher probability of relapse and poorer overall survival (OS) in the first few years after diagnosis when compared with other BC subtypes. This is observed despite its usual high sensitivity to chemotherapy. 4 Patients with earlystage TNBC seem to derive greater proportional benefit from systemic chemotherapy than patients with ER-positive early-stage BC.
Adjuvant chemotherapy significantly improves disease-free survival (DFS) and OS in comparison with observation in this subgroup of patients. 5 In patients with early-stage TNBC with excellent performance status, anthracycline-and taxane-containing regimens are the standard of care, and docetaxel plus cyclophosphamide (TC) for four cycles is considered an acceptable nonanthracycline regimen in the adjuvant setting. 5, 6 Platinum salts should not be routinely administered in the adjuvant setting of TNBC population until survival efficacy data become available. 7, 8 In the neoadjuvant setting, some studies have reported high sensitivity to platinum salts (carboplatin or cisplatin) in the TNBC population. The efficacy of neoadjuvant cisplatin in patients with localized or locally advanced TNBC was assessed in a phase II trial. In this study, 28 patients with stage II or III TNBC were treated with four cycles of cisplatin at 75 mg/m 2 every 21 days. Six (22%) of 28 patients achieved pathologic complete responses (pCRs). 9 In the Cancer and Leukemia Group B (CALGB) 40603 trial, carboplatin significantly improved pCR in patients with stages II-III TNBC when added to weekly paclitaxel for 12 weeks followed by doxorubicin plus cyclophosphamide once every 2 weeks for four cycles (54% vs 41%; P = 0.0029). 10 Patients who achieved a pCR had improved OS and event-free survival compared with patients who did not achieve a pCR. However, there was no improvement in survival outcome with the addition of either carboplatin or bevacizumab to the standard neoadjuvant chemotherapy regimen. The GeparSixto study showed an improvement in pCR among 315 patients with TNBC treated with 18 weeks of neoadjuvant paclitaxel once per week, nonpegylated liposomal doxorubicin once per week and bevacizumab once every 21 days who received carboplatin once per week compared with those who did not (pCR, 53% vs 37%; P = 0.005). 11 At 3-year follow-up, DFS was improved in patients who received carboplatin compared with controls (hazard ratio [HR], 0.56; P = 0.035). However, the GEICAM 2006-03 study showed no improvement in pCR with the addition of carboplatin to epirubicin and cyclophosphamide for four cycles followed by docetaxel for four cycles (pCR of 30% in both arms; n = 94). 12 Metastatic TNBC is associated with a more aggressive clinical course compared with other BC subtypes. Despite its high sensitivity to chemotherapy, advanced TNBC has poor outcome with conventional chemotherapy regimens. 13 Metastatic TNBC represents a continuing challenge because, when compared with other BC subtypes, it is associated with a higher frequency of progression, shorter progression-free survival (PFS) and poorer OS. The median OS for metastatic TNBC is about 9-12 months with conventional cytotoxic agents. 13, 14 
MOLECULAR BIOLOGY OF TNBC: GENE EXPRESSION AND INTRINSIC MOLECULAR SUBTYPES
TNBC is a heterogeneous disease with distinct molecular subtypes that respond differentially to chemotherapy and targeted agents. Recent genomic analyses have demonstrated the profound inter-and intratumoural heterogeneity of TNBC, which may in part explain the disappointing results from early trials with targeted agents in unselected TNBC. The heterogeneity of TNBC is further highlighted by the high prevalence of rare histopathological subtypes, such as metaplastic (90%), medullary (95%), adenoid cystic (90-100%) and apocrine (40-60%) carcinomas 3 Most of TNBCs have genomic instability, and one alteration that occurs in the majority of TNBCs is mutation or loss of TP53. According to the Cancer Genome Atlas (TGCA), 68% of TNBC cases have TP53 mutations in addition to homozygous deletion of the gene (3%) or MDM2/4 amplifications (7%). 15, 16 Another study showed that TP53 mutations were the most frequent clonal event (54%), followed by PIK3CA mutations (11%). 17 On the other hand, deleterious mutations in predisposition genes are present at high frequency in patients with TNBC. In a recent study, testing germline genetic mutations in patients with TNBC, deleterious mutations were identified in 15% of all cases. Of these, 11% had mutations in the BRCA1 (8%) and BRCA2 (3%) genes. Deleterious mutations in 15 other predisposition genes were detected in 4% of patients, with the majority observed in genes involved in homologous recombination (HHRR), including PALB2, BARD1, RAD51D, RAD51C and BRIP1.
Besides, patients with TNBC with germline mutations were diagnosed at an earlier age and had higher grade tumors than those without mutations. This study suggests that all patients with TNBC, regardless of age at diagnosis or family history of cancer, should be considered for germline genetic testing of BRCA1 and BRCA2. 18 Gene expression profiling has had a considerable impact on the understanding of BC biology. During the last two decades, it has extensively characterized five intrinsic molecular subtypes of BC (luminal A, luminal B, HER-2 enriched, basal-like and claudin-low) and a normal breast-like group. 19, 20 According to the PAM50 assay (which excludes claudin-low subtype), within TNBC, all the intrinsic molecular subtypes can be identified, although the vast majority falls into the basal-like subtype. In a combined analysis of 868 triple negative tumors, 86%, 9%, 3% and 2%
were identified as basal-like, HER2-enriched, luminal B and luminal A, respectively. 21 However, when claudin-low subtype is included, 49% of TNBCs are basal-like, 30% claudin-low, 9% HER2-enriched, 6% luminal B, 5% luminal A and 1% normal breast-like. 22 The basal-like subtype is characterized at the RNA and protein level by the high expression of proliferation-related genes However, the MSL subtype differs in that it expresses low levels of proliferation genes and is enriched for mesenchymal stem cell-associated genes. The LAR subtype displayed luminal gene expression patterns and is heavily enriched for genes involved in steroid synthesis and androgen/estrogen metabolism, including high levels of androgen receptor (AR) and its downstream targets and coactivators.
In conclusion, it has become appreciated that TNBC is not one disease, but in fact represents multiple disease types, each of which may require a unique treatment.
FIRST-LINE THERAPY FOR METASTATIC TNBC
Despite general improvements in the management of advanced BC, metastatic TNBC represents a continuing challenge because, when compared with other BC subtypes, it is associated with a higher frequency of progression, shorter PFS and poorer OS. The median OS for metastatic TNBC is about 9-12 months with conventional cytotoxic agents. 13, 14 To date, cytotoxic chemotherapy is the main systemic treatment for patients with advanced TNBC. Different targeted approaches such as DNA repair agents, poly-ADPribose-polymerase (PARP) inhibitors, Epidermal Growth Factor Receptor (EGFR) inhibitors, antiangiogenic agents or checkpoint kinase 1 inhibitors (with or without chemotherapy) have been investigated for the treatment of metastatic TNBC; however, these agents have not produced substantial improvements in TNBC outcomes. 27, 28 Hence, there is not a standard of care in the first-line therapy for advanced TNBC. The efficacy of different chemotherapy regimens containing taxanes, anthracyclines, gemcitabine and/or platinum salts has been evaluated as first-line therapy for metastatic TNBC in several studies (Table 1) .
Monochemotherapy in the first-line therapy of patients with metastatic TNBC is associated with an objective response rate (ORR) of 25-35%, a modest PFS (median PFS of less than 6 months) and a median OS of less than 12 months. In the first-line therapy of patients with metastatic TNBC, treatment with taxanes (weekly paclitaxel or triweekly docetaxel) is associated with an ORR of 30-35%, a median PFS of 4-5 months and a median OS of approximately 12 months. 29, 30 Platinum salts (cisplatin or carboplatin) as monotherapy have also been evaluated in the first-line therapy of these patients. In TBCRC009 study, patients with metastatic TNBC received first-or second-line cisplatin (75 mg/m 2 ) or carboplatin (area under the concentration-time curve 6) by physician's choice once every 3 weeks. The ORR was 29% with first-line therapy (35% with cisplatin and 23% with carboplatin).
The median PFS was 2.9 months and OS was 11.0 months. 31 months and a median OS of 12.6 months. 33 In a phase III randomized trial, CBCSG006 study, cisplatin plus gemcitabine was compared to paclitaxel plus gemcitabine as first-line therapy for metastatic TNBC. A total of 240 patients were included in this study, 120 patients were randomly assigned to the cisplatin plus gemcitabine group and 120 to the paclitaxel plus gemcitabine group. The HR for PFS was 0.69 (95% Confidence Interval [CI]: 0.52-0.91; P = 0.009), favoring the cisplatin plus gemcitabine group. Median PFS was 7.7 months in the cisplatin plus gemcitabine group and 6.5 months in the paclitaxel plus gemcitabine group. ORR was 64% in the cisplatin plus gemcitabine group and 49% in the paclitaxel plus gemcitabine group. There were no significant differences in OS between the treatment groups. 34 Bevacizumab, an antivascular endothelial growth factor monoclonal antibody, has been evaluated for the treatment of advanced BC across several phase III studies. 28, 29, 35 The grouped analysis of data 0.79-1.16). 36 In the ATHENA study, the combination of bevacizumab plus chemotherapy in 585 patients with metastatic TNBC was associated with an ORR of 49% (including complete responses in 10%).
The median time to progression was 7.2 months (95% CI: 6.6-7.8), the median OS was 18.3 months (95% CI: 16.4-19.7) and the 1-year OS rate was 60%. 37 In the IMELDA study, maintenance capecitabine and bevacizumab (vs bevacizumab alone) after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic BC was associated with significantly improved PFS and OS. This improvement in the outcome was also seen in the TNBC subgroup (Table 2) . 38 Hence, this strategy could be interesting in first-line therapy of patients with metastatic TNBC.
NEW TREATMENT OPTIONS FOR METASTATIC TNBC
There is currently no molecular classification of TNBC that has identified genomic targets that are of proven therapeutic utility. After neoadjuvant and/or adjuvant chemotherapy, patients with early TNBC n = number of patients with metastatic triple negative breast cancer; NR = not reported; ORR = overall response rate; OS = overall survival; PFS = progression-free survival.
TA B L E 1 Efficacy of different chemotherapy regimens as first-line therapy for metastatic TNBC
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to be particularly sensitive to the cytotoxic effects of DNA interstrand cross-linking agents such as cisplatin and carboplatin and PARP inhibitors. 30, 31, 33, 39 PARPs are a large family of multifunctional enzymes, the most abun- of patients experienced stable disease with avelumab, for a disease control rate of 28%. After a median follow-up of 10 months, the ORR in patients with PD-L1-positive metastatic BC was 33%. In patients with PD-L1-positive TNBC, the ORR was 44% with avelumab. Across the full study population, which included PD-L1-negative patients, the ORR was 4.8%. Of those who responded, five had TNBC (8.6%), four of which were PD-L1-positive. Responses were also observed in patients with HER2-negative/HR-positive BC (2.8%) and for those with HER2-positive disease (3.8%).
CONCLUSIONS
TNBC is a heterogeneous disease, is frequently of high histologic grade, present at an advanced stage, is typically more aggressive and difficult 
